KJ-14002 is under clinical development by Kukje Pharmaceutical Industry and currently in Phase II for Ocular Hypertension. According to GlobalData, Phase II drugs for Ocular Hypertension have a 33% phase transition success rate (PTSR) indication benchmark for progressing into Phase III. GlobalData’s report assesses how KJ-14002’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.
GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.
KJ-14002 overview
KJ-14002 is under development for the treatment of open-angle glaucoma and ocular hypertension. The drug candidate is administered through oral route in the form of a tablet and through ophthalmic route as a solution and is an incrementally modified three drug combination treatment. It is developed based on DDS platform technology.
Kukje Pharmaceutical Industry overview
Kukje Pharmaceutical Industry (Kukje) is a pharmaceutical company that focuses on research and development, particularly in the field of ophthalmic diseases. The company’s main activities include the production of pharmaceutical raw materials and finished drugs, with a significant emphasis on the development of new and revised drugs for conditions such as macular degeneration and glaucoma. Kukje Pharma offers specialized pharmaceutical products, including antibiotics, cardiovascular agents, antidiabetics, and anti-inflammatory drugs. Its product Tagen-F, a medicine for treating retinal degeneration caused by diabetes. The company operates in China, Vietnam, the Middle East, and Africa. Kukje is headquartered in Seongnam-si, Gyeonggi-do, South Korea.
For a complete picture of KJ-14002’s drug-specific PTSR and LoA scores, buy the report here.
Data Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in clinical development (PTSR), as well as how likely the drug will be approved (LoA). This is based on a combination of machine learning and a proprietary algorithm to process data points from various databases found on GlobalData’s Pharmaceutical Intelligence Center.
